{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-22-117650","form_type":"8-K","ticker":"PMN","cik":"0001374339","company_name":"ProMIS Neurosciences Inc.","filed_at":"2022-11-14T23:59:59+00:00","discovered_at":"2026-05-14T18:03:50.359826+00:00","generated_at":"2026-06-21T19:44:24.569428+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.55,"calibrated_materiality_score":0.55,"confidence":"high","headline":"ProMIS Q3 net loss $6.0M vs $1.2M YoY; cash down to $4.0M; CEO change and $7.4M PIPE closed","bullets":["Net loss of $6.0M for Q3 2022, up from $1.2M in Q3 2021; R&D expenses rose to $4.6M from $0.8M.","Cash and equivalents $4.0M at Sep 30, 2022, down from $17.0M at Dec 31, 2021; Oct 2022 PIPE netted $6.4M.","Gail Farfel appointed CEO effective Sep 19, 2022; co-founder Eugene Williams remains Chairman.","IND submission for Alzheimer's candidate PMN310 progressing; first subject enrollment expected H1 2023.","ALS candidate PMN267 and MSA candidate PMN442 advancing; vaccine program ongoing."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-22-117650","json":"https://secwatch.observer/filing/0001104659-22-117650.json","markdown":"https://secwatch.observer/filing/0001104659-22-117650.md","text":"https://secwatch.observer/filing/0001104659-22-117650.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1374339/000110465922117650/0001104659-22-117650-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1374339/000110465922117650/tm2224043d2_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-21T19:44:24.569428+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"8ffad844c26c95545920d8835150f5d50fd962c6","claim":"ProMIS Neurosciences Inc. reported the third quarter ended September 30, 2022 results: net income Net loss was $6.0 million.","evidence_excerpt":"Net loss was $6.0 million for the third quarter ended September 30, 2022, compared to $1.2 million for the same period in 2021.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1374339/000110465922117650/0001104659-22-117650-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the third quarter ended September 30, 2022"},{"label":"Net income","value":"Net loss was $6.0 million"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}